N@N

Facet Biotech Announces Four Presentations at American Society of Hematology Annual Meeting

_{//health-fitness.news-articles.net/content/2009/ .. erican-society-of-hematology-annual-meeting.html}
^{Published in Health and Fitness on Thursday, November 19th 2009 at 5:38 GMT by Market Wire}  

REDWOOD CITY, CA--(Marketwire - November 19, 2009) - Facet Biotech Corporation (NASDAQ: [ FACT ]) today announced that data for the company's elotuzumab and TRU-016 development programs will be presented at the American Society of Hematology (ASH) 2009 Annual Meeting and Exposition taking place in New Orleans, La. at the Ernest N. Morial Convention Center, December 5 - 8, 2009.

 Oral Presentation Abstract: 432 Title: A Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results. Lead Investigator: Sagar Lonial, MD, Winship Cancer Institute, Emory University When: Monday, December 7, 2009 at 11:45 a.m. CT Where: Hall F Poster Presentations Abstract: 1744 Title: Glycovariant CD37 Small Modular Immuno-Pharmaceutical (TruADhanCe™ SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary Chronic Lymphocytic Leukemia Cells. Lead Investigator: Sarwish Rafiq, MD, Ohio State University Comprehensive Cancer Center When: Saturday, December 5, 2009 at 5:30 p.m. - 7:30 p.m. CT Where: Hall E, Poster Board I-766 Abstract: 3876 Title: A Phase 1/2 Study of Elotuzumab in Combination with Bortezomib in Patients with Multiple Myeloma with One to Three Prior Therapies: Interim Results. Lead Investigator: Andrzej J. Jakubowiak, MD, University of Michigan Comprehensive Cancer Center When: Monday, December 7, 2009 at 6:00 p.m. - 8:00 p.m. CT Where: Hall E, Poster Board III-812 Abstract: 3424 Title: A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIP™) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity. Lead Investigator: Leslie Andritsos, MD, The Ohio State University When: Monday, December 7, 2009 at 6:00 p.m. - 8:00 p.m. CT Where: Hall E, Poster Board III-361 

The ASH 2009 program and abstracts are available online and can be accessed at: [ http://www.hematology.org/Meetings/Annual-Meeting/Abstracts/3689.aspx ].

About Elotuzumab and TRU-016

Elotuzumab is a humanized monoclonal antibody directed against CS1 that Facet is developing for multiple myeloma in collaboration with Bristol-Myers Squibb Company. TRU-016 is a SMIP protein therapeutic targeting CD37 that Facet is developing in collaboration with Trubion Pharmaceuticals, Inc. TRU-016 is currently in clinical development for chronic lymphocytic leukemia and may be explored in non-Hodgkin's lymphoma and autoimmune diseases.

About Facet Biotech

Facet Biotech is a biotechnology company dedicated to advancing its pipeline of five clinical-stage products, leveraging its research and development capabilities to identify and develop new oncology drugs and applying its proprietary next-generation protein engineering technologies to potentially improve the clinical performance of protein therapeutics. Facet Biotech Corporation launched in December 2008 as a spin-off from PDL BioPharma, Inc.

NOTE: Facet Biotech and the Facet Biotech logo are considered trademarks of Facet Biotech Corporation.